Digital Delivery of Apolipoprotein E Genotype and Phosphorylated Tau 217 Results: The eSMARTER Randomized Clinical Trial

Importance: Patients are increasingly learning Alzheimer disease (AD) genetic and biomarker results through electronic health portals. Evaluation of alternative scalable delivery models for return of AD risk information is needed to best support patient knowledge and psychological well-being. Objective: To determine whether a digital platform is comparable to clinician-mediated telehealth sessions for returning apolipoprotein E (APOE) genotype and plasma phosphorylated tau 217 (p-tau217) results on outcomes of knowledge and psychological well-being. Design, Setting, and Participants: The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study was a noninferiority trial of a digital platform compared to clinician-mediated return of APOE genotype and optional p-tau217 results. Enrollment was conducted October 2024 through February 2025. Follow-up was completed November 2025. This was a decentralized, fully remote trial taking place across the contiguous US. Eligible participants were aged 60 to 80 years and had previously undergone APOE genotyping (without disclosure) via GeneMatch, passed psychological screening, had internet access, and could speak English. Of the 13 033 people invited by GeneMatch, 2052 accepted, and 813 were assessed for eligibility. Of 666 randomized, 651 were ultimately included. Interventions: Participants were randomized, 2:1, to the eSMARTER digital platform or study clinician-mediated return of APOE genotype. Following the 6-month post-APOE assessment, participants were offered optional p-tau217 disclosure via the same randomized modality. Main Outcomes and Measures: Primary outcomes at 1 to 7 days following APOE disclosure included changes in anxiety, disease-specific distress, and AD-related knowledge within a priori noninferiority margins. Results: A total of 674 persons were eligible and provided demographic information. Of these, 651 participants had been randomized to study clinician-mediated (n = 216) or digital disclosure (n = 435) and completed APOE disclosure (mean [SD] age, 68 [4.7] years; 439 [67%] female; mean [SD] telephone Montreal Cognitive Assessment score, 19 [2]; 66 [10%] APOE4 homozygotes, 377 [58%] heterozygotes, and 208 [32%] noncarriers) A total of 604 participants completed the study; 500 completed optional p-tau217 disclosure. Baseline characteristics were balanced across groups. At 1 to 7 days following APOE disclosure, scores on AD-related knowledge, Patient-Reported Outcomes Measurement Information System Anxiety T-score, and disease-specific distress measures met noninferiority. Conclusions and Relevance: Return of APOE genotype by the eSMARTER digital platform is noninferior to study clinician-mediated telehealth disclosure. No significant between-group differences were found following return of p-tau217 results. Together, these results suggest that this digital platform may provide an evidence-based scalable approach for returning AD genetic and biomarker results. Trial Registration: ClinicalTrials.gov Identifier: NCT06459583.

Authors

Institutions

Publication Details

Journal
JAMA Neurology
Published
2026-11-18
DOI
https://doi.org/10.1001/jamaneurol.2026.4279
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Digital Delivery of Apolipoprotein E Genotype and Phosphorylated Tau 217 Results: The eSMARTER Randomized Clinical Trial

Emily A. Largent, Jeffrey Scott Roberts, Brian Lee Egleston, Nicholas James Ashton et al.
7 links
JAMA Neurology
Dementia and Cognitive Impairment Research
article

Digital Delivery of Apolipoprotein E Genotype and Phosphorylated Tau 217 Results: The eSMARTER Randomized Clinical Trial

Emily A. Largent, Jeffrey Scott Roberts, Brian Lee Egleston, Nicholas James Ashton, Jason H. Karlawish, Cara N. Cacioppo, Kristin A. Harkins, Carolyn M. Langlois, Angela R. Bradbury, Eric M. Reiman, Hayley Salata, Jessica Enos, Samantha John, Jessica B. S. Langbaum, Rajia Mim, Claire M. Erickson, Marisa N. Denkinger, Elisabeth McCarty Wood, Laura Eppelmann, Sarah Howe, Sarah Brown, Diana DeSantiago, Camille Brown
article en

Abstract

Importance: Patients are increasingly learning Alzheimer disease (AD) genetic and biomarker results through electronic health portals. Evaluation of alternative scalable delivery models for return of AD risk information is needed to best support patient knowledge and psychological well-being. Objective: To determine whether a digital platform is comparable to clinician-mediated telehealth sessions for returning apolipoprotein E (APOE) genotype and plasma phosphorylated tau 217 (p-tau217) results on outcomes of knowledge and psychological well-being. Design, Setting, and Participants: The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study was a noninferiority trial of a digital platform compared to clinician-mediated return of APOE genotype and optional p-tau217 results. Enrollment was conducted October 2024 through February 2025. Follow-up was completed November 2025. This was a decentralized, fully remote trial taking place across the contiguous US. Eligible participants were aged 60 to 80 years and had previously undergone APOE genotyping (without disclosure) via GeneMatch, passed psychological screening, had internet access, and could speak English. Of the 13 033 people invited by GeneMatch, 2052 accepted, and 813 were assessed for eligibility. Of 666 randomized, 651 were ultimately included. Interventions: Participants were randomized, 2:1, to the eSMARTER digital platform or study clinician-mediated return of APOE genotype. Following the 6-month post-APOE assessment, participants were offered optional p-tau217 disclosure via the same randomized modality. Main Outcomes and Measures: Primary outcomes at 1 to 7 days following APOE disclosure included changes in anxiety, disease-specific distress, and AD-related knowledge within a priori noninferiority margins. Results: A total of 674 persons were eligible and provided demographic information. Of these, 651 participants had been randomized to study clinician-mediated (n = 216) or digital disclosure (n = 435) and completed APOE disclosure (mean [SD] age, 68 [4.7] years; 439 [67%] female; mean [SD] telephone Montreal Cognitive Assessment score, 19 [2]; 66 [10%] APOE4 homozygotes, 377 [58%] heterozygotes, and 208 [32%] noncarriers) A total of 604 participants completed the study; 500 completed optional p-tau217 disclosure. Baseline characteristics were balanced across groups. At 1 to 7 days following APOE disclosure, scores on AD-related knowledge, Patient-Reported Outcomes Measurement Information System Anxiety T-score, and disease-specific distress measures met noninferiority. Conclusions and Relevance: Return of APOE genotype by the eSMARTER digital platform is noninferior to study clinician-mediated telehealth disclosure. No significant between-group differences were found following return of p-tau217 results. Together, these results suggest that this digital platform may provide an evidence-based scalable approach for returning AD genetic and biomarker results. Trial Registration: ClinicalTrials.gov Identifier: NCT06459583.

JAMA Neurology
Fox Chase Cancer Center (US), St. Joseph's Hospital and Medical Center (US), University of Michigan (US), Dignity Health (US), Temple University Health System (US), Banner Sun Health Research Institute (US), Banner Alzheimer’s Institute (US), University of Pennsylvania (US)
National Institutes of Health, National Institute on Aging
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon